Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGEN-001 in persistent or recurrent ovarian cancer
NCT01118052Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Nov 2010
- Primary completion
- Jul 2016
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of IMNN-001 in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by GOG Foundation. Started Nov 2010; status: completed.
02
Drugs
IMNN-001
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01118052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01118052.